semaglutide
Semaglutide vs Tirzepatide: Kidney Survival Secrets?
In a 2025 trial of 1,200 patients, semaglutide reduced eGFR decline by 12% compared with placebo, indicating that the drug that shrinks waistlines can also protect kidneys. Both semaglutide and tirzepatide are GLP-1 based agents, but their renal safety signals differ, which matters for anyone with chronic kidney disease